{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:30:31Z","timestamp":1781109031343,"version":"3.54.1"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2013,10,24]],"date-time":"2013-10-24T00:00:00Z","timestamp":1382572800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1007\/s40265-013-0135-y","type":"journal-article","created":{"date-parts":[[2013,10,23]],"date-time":"2013-10-23T14:16:33Z","timestamp":1382537793000},"page":"1921-1933","source":"Crossref","is-referenced-by-count":22,"title":["Gender Differences in Cardiovascular Therapy: Focus on Antithrombotic Therapy and Percutaneous Coronary Intervention"],"prefix":"10.1007","volume":"73","author":[{"given":"Juan Luis","family":"Guti\u00e9rrez-Chico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julinda","family":"Mehilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,24]]},"reference":[{"issue":"6","key":"135_CR1","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jacc.2004.11.055","volume":"45","author":"AL Blomkalns","year":"2005","unstructured":"Blomkalns AL, et al. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology\/American Heart Association Guidelines) National Quality Improvement Initiative. J Am Coll Cardiol. 2005;45(6):832\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"135_CR2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/ATVBAHA.108.179796","volume":"29","author":"ES Kim","year":"2009","unstructured":"Kim ES, Menon V. Status of women in cardiovascular clinical trials. Arterioscler Thromb Vasc Biol. 2009;29(3):279\u201383.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"135_CR3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1160\/TH10-04-0232","volume":"104","author":"D Capodanno","year":"2010","unstructured":"Capodanno D, Angiolillo DJ. Impact of race and gender on antithrombotic therapy. Thromb Haemost. 2010;104(3):471\u201384.","journal-title":"Thromb Haemost"},{"issue":"3","key":"135_CR4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women\u2019s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321\u201333.","journal-title":"JAMA"},{"issue":"13","key":"135_CR5","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","volume":"352","author":"PM Ridker","year":"2005","unstructured":"Ridker PM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352(13):1293\u2013304.","journal-title":"N Engl J Med"},{"issue":"1","key":"135_CR6","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1161\/CIR.0b013e31823ac046","volume":"125","author":"VL Roger","year":"2012","unstructured":"Roger VL, et al. Heart disease and stroke statistics\u20132012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2\u2013220.","journal-title":"Circulation"},{"issue":"5","key":"135_CR7","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1160\/TH08-09-0624","volume":"102","author":"T Eshel-Green","year":"2009","unstructured":"Eshel-Green T, et al. Effect of sex difference on platelet adhesion, spreading and aggregate formation under flow. Thromb Haemost. 2009;102(5):958\u201365.","journal-title":"Thromb Haemost"},{"issue":"2","key":"135_CR8","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1161\/01.ATV.0000110445.95304.91","volume":"24","author":"XH Leng","year":"2004","unstructured":"Leng XH, et al. Platelets of female mice are intrinsically more sensitive to agonists than are platelets of males. Arterioscler Thromb Vasc Biol. 2004;24(2):376\u201381.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"135_CR9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1507\/endocrj.48.33","volume":"48","author":"SF Haque","year":"2001","unstructured":"Haque SF, et al. Sex difference in platelet aggregation detected by new aggregometry using light scattering. Endocr J. 2001;48(1):33\u201341.","journal-title":"Endocr J"},{"issue":"2","key":"135_CR10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2141.1977.tb06847.x","volume":"37","author":"RF Stevens","year":"1977","unstructured":"Stevens RF, Alexander MK. A sex difference in the platelet count. Br J Haematol. 1977;37(2):295\u2013300.","journal-title":"Br J Haematol"},{"issue":"2","key":"135_CR11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.7326\/0003-4819-89-2-157","volume":"89","author":"T Gordon","year":"1978","unstructured":"Gordon T, et al. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med. 1978;89(2):157\u201361.","journal-title":"Ann Intern Med"},{"issue":"1","key":"135_CR12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9378(81)90410-5","volume":"139","author":"L Rosenberg","year":"1981","unstructured":"Rosenberg L, et al. Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol. 1981;139(1):47\u201351.","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"135_CR13","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1210\/jc.80.6.1832","volume":"80","author":"T Mikkola","year":"1995","unstructured":"Mikkola T, et al. 17 beta-estradiol stimulates prostacyclin, but not endothelin-1, production in human vascular endothelial cells. J Clin Endocrinol Metab. 1995;80(6):1832\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"135_CR14","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1161\/01.RES.81.5.885","volume":"81","author":"T Caulin-Glaser","year":"1997","unstructured":"Caulin-Glaser T, et al. 17 beta-estradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca2+ mobilization. Circ Res. 1997;81(5):885\u201392.","journal-title":"Circ Res"},{"key":"135_CR15","doi-asserted-by":"crossref","unstructured":"Arora S, et al. Estrogen improves endothelial function. J Vasc Surg. 1998;27(6):1141\u20136 (discussion 1147).","DOI":"10.1016\/S0741-5214(98)70016-3"},{"issue":"11","key":"135_CR16","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1161\/01.CIR.91.11.2742","volume":"91","author":"AA Ajayi","year":"1995","unstructured":"Ajayi AA, Mathur R, Halushka PV. Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation. 1995;91(11):2742\u20137.","journal-title":"Circulation"},{"issue":"9","key":"135_CR17","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/0003-4819-132-9-200005020-00002","volume":"132","author":"D Grady","year":"2000","unstructured":"Grady D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen\/progestin Replacement Study. Ann Intern Med. 2000;132(9):689\u201396.","journal-title":"Ann Intern Med"},{"issue":"23","key":"135_CR18","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJM199906103402306","volume":"340","author":"ME Mendelsohn","year":"1999","unstructured":"Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340(23):1801\u201311.","journal-title":"N Engl J Med"},{"issue":"1","key":"135_CR19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0021-9150(88)90303-6","volume":"71","author":"C Bonithon-Kopp","year":"1988","unstructured":"Bonithon-Kopp C, et al. Relationship between sex hormones and haemostatic factors in healthy middle-aged men. Atherosclerosis. 1988;71(1):71\u20136.","journal-title":"Atherosclerosis"},{"issue":"2","key":"135_CR20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1055\/s-0038-1650033","volume":"43","author":"B Bain","year":"1980","unstructured":"Bain B, Forster T. A sex difference in the bleeding time. Thromb Haemost. 1980;43(2):131\u20132.","journal-title":"Thromb Haemost"},{"issue":"7","key":"135_CR21","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jacc.2007.10.040","volume":"51","author":"G Ndrepepa","year":"2008","unstructured":"Ndrepepa G, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol. 2008;51(7):690\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"135_CR22","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/eurheartj\/ehm019","volume":"28","author":"SV Rao","year":"2007","unstructured":"Rao SV, et al. Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28(10):1193\u2013204.","journal-title":"Eur Heart J"},{"key":"135_CR23","doi-asserted-by":"crossref","unstructured":"Mehilli J, et al. Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial. Am Heart J. 2007;154(1):158 e1\u20137.","DOI":"10.1016\/j.ahj.2007.03.050"},{"issue":"9","key":"135_CR24","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.amjcard.2009.01.030","volume":"103","author":"AJ Lansky","year":"2009","unstructured":"Lansky AJ, et al. Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial). Am J Cardiol. 2009;103(9):1196\u2013203.","journal-title":"Am J Cardiol"},{"issue":"1","key":"135_CR25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1079\/BJN19740060","volume":"32","author":"JV Durnin","year":"1974","unstructured":"Durnin JV, Womersley J. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72\u00a0years. Br J Nutr. 1974;32(1):77\u201397.","journal-title":"Br J Nutr"},{"issue":"6","key":"135_CR26","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461\u201370.","journal-title":"Ann Intern Med"},{"issue":"13","key":"135_CR27","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1161\/CIRCULATIONAHA.106.620815","volume":"114","author":"KP Alexander","year":"2006","unstructured":"Alexander KP, et al. Sex differences in major bleeding with glycoprotein IIb\/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC\/AHA guidelines) initiative. Circulation. 2006;114(13):1380\u20137.","journal-title":"Circulation"},{"issue":"22","key":"135_CR28","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","volume":"353","author":"C Patrono","year":"2005","unstructured":"Patrono C, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353(22):2373\u201383.","journal-title":"N Engl J Med"},{"issue":"12","key":"135_CR29","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1001\/jama.295.12.1420","volume":"295","author":"DM Becker","year":"2006","unstructured":"Becker DM, et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA. 2006;295(12):1420\u20137.","journal-title":"JAMA"},{"issue":"6","key":"135_CR30","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0735-1097(02)03014-0","volume":"41","author":"PA Gum","year":"2003","unstructured":"Gum PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41(6):961\u20135.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"135_CR31","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.amjcard.2007.12.038","volume":"101","author":"R Qayyum","year":"2008","unstructured":"Qayyum R, et al. Platelet inhibition by aspirin 81 and 325\u00a0mg\/day in men versus women without clinically apparent cardiovascular disease. Am J Cardiol. 2008;101(9):1359\u201363.","journal-title":"Am J Cardiol"},{"issue":"17","key":"135_CR32","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1161\/CIRCULATIONAHA.108.768283","volume":"118","author":"JW Eikelboom","year":"2008","unstructured":"Eikelboom JW, et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation. 2008;118(17):1705\u201312.","journal-title":"Circulation"},{"issue":"14","key":"135_CR33","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1161\/01.CIR.0000013777.21160.07","volume":"105","author":"JW Eikelboom","year":"2002","unstructured":"Eikelboom JW, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105(14):1650\u20135.","journal-title":"Circulation"},{"issue":"3","key":"135_CR34","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.295.3.306","volume":"295","author":"JS Berger","year":"2006","unstructured":"Berger JS, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295(3):306\u201313.","journal-title":"JAMA"},{"key":"135_CR35","doi-asserted-by":"crossref","unstructured":"Antithrombotic Trialists\u2019 (ATT) Collaboration, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849\u201360.","DOI":"10.1016\/S0140-6736(09)60503-1"},{"issue":"16","key":"135_CR36","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1093\/eurheartj\/ehi397","volume":"26","author":"N Jochmann","year":"2005","unstructured":"Jochmann N, et al. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J. 2005;26(16):1585\u201395.","journal-title":"Eur Heart J"},{"issue":"1","key":"135_CR37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1160\/TH09-03-0185","volume":"102","author":"JL Ferreiro","year":"2009","unstructured":"Ferreiro JL, Angiolillo DJ. Clopidogrel response variability: current status and future directions. Thromb Haemost. 2009;102(1):7\u201314.","journal-title":"Thromb Haemost"},{"issue":"7","key":"135_CR38","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"S Yusuf","year":"2001","unstructured":"Yusuf S, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494\u2013502.","journal-title":"N Engl J Med"},{"issue":"9281","key":"135_CR39","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","volume":"358","author":"SR Mehta","year":"2001","unstructured":"Mehta SR, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527\u201333.","journal-title":"Lancet"},{"issue":"19","key":"135_CR40","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","volume":"288","author":"SR Steinhubl","year":"2002","unstructured":"Steinhubl SR, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19):2411\u201320.","journal-title":"JAMA"},{"issue":"12","key":"135_CR41","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","volume":"352","author":"MS Sabatine","year":"2005","unstructured":"Sabatine MS, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179\u201389.","journal-title":"N Engl J Med"},{"issue":"16","key":"135_CR42","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","volume":"354","author":"DL Bhatt","year":"2006","unstructured":"Bhatt DL, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706\u201317.","journal-title":"N Engl J Med"},{"issue":"21","key":"135_CR43","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jacc.2009.05.074","volume":"54","author":"JS Berger","year":"2009","unstructured":"Berger JS, et al. The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J Am Coll Cardiol. 2009;54(21):1935\u201345.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"135_CR44","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001\u201315.","journal-title":"N Engl J Med"},{"issue":"11","key":"135_CR45","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045\u201357.","journal-title":"N Engl J Med"},{"issue":"1","key":"135_CR46","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1172\/JCI110973","volume":"72","author":"BS Coller","year":"1983","unstructured":"Coller BS, et al. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and\/or IIIa. J Clin Invest. 1983;72(1):325\u201338.","journal-title":"J Clin Invest"},{"issue":"4","key":"135_CR47","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1161\/hc2901.093500","volume":"104","author":"BE Tardiff","year":"2001","unstructured":"Tardiff BE, et al. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT. Circulation. 2001;104(4):399\u2013405.","journal-title":"Circulation"},{"issue":"2","key":"135_CR48","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0735-1097(00)00746-4","volume":"36","author":"L Cho","year":"2000","unstructured":"Cho L, et al. Clinical benefit of glycoprotein IIb\/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb\/IIIa blockade. Evaluation of Platelet IIb\/IIIa Inhibitor for Stent. J Am Coll Cardiol. 2000;36(2):381\u20136.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"135_CR49","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0735-1097(02)02120-4","volume":"40","author":"LS Fernandes","year":"2002","unstructured":"Fernandes LS, et al. Is glycoprotein IIb\/IIIa antagonism as effective in women as in men following percutaneous coronary intervention? Lessons from the ESPRIT study. J Am Coll Cardiol. 2002;40(6):1085\u201391.","journal-title":"J Am Coll Cardiol"},{"issue":"9302","key":"135_CR50","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(02)07442-1","volume":"359","author":"E Boersma","year":"2002","unstructured":"Boersma E, et al. Platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002;359(9302):189\u201398.","journal-title":"Lancet"},{"issue":"23","key":"135_CR51","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1161\/CIRCULATIONAHA.110.002683","volume":"123","author":"W Hochholzer","year":"2011","unstructured":"Hochholzer W, et al. Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation. 2011;123(23):2681\u20139.","journal-title":"Circulation"},{"issue":"21","key":"135_CR52","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1056\/NEJMoa1109596","volume":"365","author":"A Kastrati","year":"2011","unstructured":"Kastrati A, et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med. 2011;365(21):1980\u20139.","journal-title":"N Engl J Med"},{"issue":"5 Suppl","key":"135_CR53","doi-asserted-by":"crossref","first-page":"489S","DOI":"10.1378\/chest.114.5_Supplement.489S","volume":"114","author":"J Hirsh","year":"1998","unstructured":"Hirsh J, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1998;114(5 Suppl):489S\u2013510S.","journal-title":"Chest"},{"issue":"5","key":"135_CR54","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/01.CIR.93.5.870","volume":"93","author":"CB Granger","year":"1996","unstructured":"Granger CB, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation. 1996;93(5):870\u20138.","journal-title":"Circulation"},{"issue":"9","key":"135_CR55","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1111\/j.1538-7836.2011.04402.x","volume":"9","author":"N Falvo","year":"2011","unstructured":"Falvo N, et al. Heparin-associated thrombocytopenia in 24,401 patients with venous thromboembolism: findings from the RIETE Registry. J Thromb Haemost. 2011;9(9):1761\u20138.","journal-title":"J Thromb Haemost"},{"issue":"7","key":"135_CR56","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0735-1097(97)00094-6","volume":"29","author":"The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators","year":"1997","unstructured":"The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina results of TIMI 11A. J Am Coll Cardiol. 1997;29(7):1474\u201382.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"135_CR57","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1067\/mhj.2002.120774","volume":"143","author":"RC Becker","year":"2002","unstructured":"Becker RC, et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J. 2002;143(5):753\u20139.","journal-title":"Am Heart J"},{"issue":"9001","key":"135_CR58","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0140-6736(96)91270-2","volume":"347","author":"Fragmin during Instability in Coronary Artery Disease (FRISC) study group","year":"1996","unstructured":"Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet. 1996;347(9001):561\u20138.","journal-title":"Lancet"},{"issue":"1","key":"135_CR59","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0002-8703(99)70461-8","volume":"137","author":"H Toss","year":"1999","unstructured":"Toss H, Wallentin L, Siegbahn A. Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease. Am Heart J. 1999;137(1):72\u20138.","journal-title":"Am Heart J"},{"issue":"3","key":"135_CR60","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1023\/A:1015259706522","volume":"12","author":"M Cohen","year":"2001","unstructured":"Cohen M, et al. Enoxaparin in unstable angina\/non-ST-segment elevation myocardial infarction: treatment benefits in prespecified subgroups. J Thromb Thrombolysis. 2001;12(3):199\u2013206.","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"135_CR61","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.ahj.2006.08.002","volume":"152","author":"HD White","year":"2006","unstructured":"White HD, et al. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb\/IIIa Inhibitors (SYNERGY) trial. Am Heart J. 2006;152(6):1042\u201350.","journal-title":"Am Heart J"},{"issue":"14","key":"135_CR62","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa060898","volume":"354","author":"EM Antman","year":"2006","unstructured":"Antman EM, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006;354(14):1477\u201388.","journal-title":"N Engl J Med"},{"issue":"22","key":"135_CR63","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1161\/CIRCULATIONAHA.106.679548","volume":"115","author":"JL Mega","year":"2007","unstructured":"Mega JL, et al. Outcomes and optimal antithrombotic therapy in women undergoing fibrinolysis for ST-elevation myocardial infarction. Circulation. 2007;115(22):2822\u20138.","journal-title":"Circulation"},{"issue":"4","key":"135_CR64","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1161\/CIR.0b013e3182742c84","volume":"127","author":"PT O\u2019Gara","year":"2013","unstructured":"O\u2019Gara PT, et al. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):529\u201355.","journal-title":"Circulation"},{"issue":"18","key":"135_CR65","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1161\/CIR.0b013e318212bb8b","volume":"123","author":"JL Anderson","year":"2011","unstructured":"Anderson JL, et al. 2011 ACCF\/AHA Focused Update Incorporated Into the ACC\/AHA 2007 Guidelines for the Management of Patients With Unstable Angina\/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123(18):e426\u2013579.","journal-title":"Circulation"},{"key":"135_CR66","doi-asserted-by":"crossref","unstructured":"Chacko M, et al. Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. Am Heart J. 2006;151(5):1032 e1\u20137.","DOI":"10.1016\/j.ahj.2006.02.012"},{"issue":"6","key":"135_CR67","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/jama.292.6.696","volume":"292","author":"AM Lincoff","year":"2004","unstructured":"Lincoff AM, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb\/IIIa blockade vs heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA. 2004;292(6):696\u2013703.","journal-title":"JAMA"},{"issue":"7","key":"135_CR68","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","volume":"289","author":"AM Lincoff","year":"2003","unstructured":"Lincoff AM, et al. Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289(7):853\u201363.","journal-title":"JAMA"},{"issue":"21","key":"135_CR69","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","volume":"355","author":"GW Stone","year":"2006","unstructured":"Stone GW, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355(21):2203\u201316.","journal-title":"N Engl J Med"},{"issue":"9565","key":"135_CR70","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0140-6736(07)60450-4","volume":"369","author":"GW Stone","year":"2007","unstructured":"Stone GW, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet. 2007;369(9565):907\u201319.","journal-title":"Lancet"},{"issue":"5","key":"135_CR71","doi-asserted-by":"crossref","first-page":"610","DOI":"10.4244\/EIJV3I5A109","volume":"3","author":"JK Madsen","year":"2008","unstructured":"Madsen JK, et al. Ischaemic events and bleeding in patients undergoing percutaneous coronary intervention with concomitant bivalirudin treatment. EuroIntervention. 2008;3(5):610\u20136.","journal-title":"EuroIntervention"},{"issue":"21","key":"135_CR72","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","volume":"358","author":"GW Stone","year":"2008","unstructured":"Stone GW, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358(21):2218\u201330.","journal-title":"N Engl J Med"},{"issue":"9696","key":"135_CR73","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(09)61484-7","volume":"374","author":"R Mehran","year":"2009","unstructured":"Mehran R, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet. 2009;374(9696):1149\u201359.","journal-title":"Lancet"},{"issue":"4","key":"135_CR74","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ahj.2012.12.021","volume":"165","author":"J Mehilli","year":"2013","unstructured":"Mehilli J, et al. Sex-related effectiveness of bivalirudin versus abciximab and heparin in non-ST-segment elevation myocardial infarction. Am Heart J. 2013;165(4):537\u201343.","journal-title":"Am Heart J"},{"issue":"12","key":"135_CR75","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351.","journal-title":"N Engl J Med"},{"issue":"3","key":"135_CR76","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1592\/phco.20.4.318.34881","volume":"20","author":"SK Swan","year":"2000","unstructured":"Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy. 2000;20(3):318\u201329.","journal-title":"Pharmacotherapy"},{"issue":"6","key":"135_CR77","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1089\/jwh.2006.0167","volume":"16","author":"IK Jang","year":"2007","unstructured":"Jang IK, et al. Argatroban therapy in women with heparin-induced thrombocytopenia. J Womens Health (Larchmt). 2007;16(6):895\u2013901.","journal-title":"J Womens Health (Larchmt)"},{"key":"135_CR78","doi-asserted-by":"crossref","unstructured":"Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354(14):1464\u201376.","DOI":"10.1056\/NEJMoa055443"},{"issue":"13","key":"135_CR79","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","volume":"295","author":"S Yusuf","year":"2006","unstructured":"Yusuf S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295(13):1519\u201330.","journal-title":"JAMA"},{"key":"135_CR80","doi-asserted-by":"crossref","unstructured":"EINSTEIN Investigators, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499\u2013510.","DOI":"10.1056\/NEJMoa1007903"},{"key":"135_CR81","doi-asserted-by":"crossref","unstructured":"EINSTEIN-PE Investigators, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287\u201397.","DOI":"10.1056\/NEJMoa1113572"},{"issue":"10","key":"135_CR82","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391.","journal-title":"N Engl J Med"},{"issue":"11","key":"135_CR83","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392.","journal-title":"N Engl J Med"},{"key":"135_CR84","doi-asserted-by":"crossref","unstructured":"The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406-1415.","DOI":"10.1056\/NEJMoa1306638"},{"issue":"18","key":"135_CR85","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1001\/jama.2012.3490","volume":"307","author":"M Avgil Tsadok","year":"2012","unstructured":"Avgil Tsadok M, et al. Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. JAMA. 2012;307(18):1952\u20138.","journal-title":"JAMA"},{"issue":"12","key":"135_CR86","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.105.553438","volume":"112","author":"MC Fang","year":"2005","unstructured":"Fang MC, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation. 2005;112(12):1687\u201391.","journal-title":"Circulation"},{"issue":"16","key":"135_CR87","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1093\/eurheartj\/ehl103","volume":"27","author":"M Gomberg-Maitland","year":"2006","unstructured":"Gomberg-Maitland M, et al. Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. Eur Heart J. 2006;27(16):1947\u201353.","journal-title":"Eur Heart J"},{"issue":"6","key":"135_CR88","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1378\/chest.127.6.2049","volume":"127","author":"D Garcia","year":"2005","unstructured":"Garcia D, et al. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest. 2005;127(6):2049\u201356.","journal-title":"Chest"},{"issue":"8","key":"135_CR89","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.2012.199","volume":"307","author":"JG Canto","year":"2012","unstructured":"Canto JG, et al. Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. JAMA. 2012;307(8):813\u201322.","journal-title":"JAMA"},{"issue":"6","key":"135_CR90","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jacc.2004.11.054","volume":"45","author":"J Mehilli","year":"2005","unstructured":"Mehilli J, et al. Gender and myocardial salvage after reperfusion treatment in acute myocardial infarction. J Am Coll Cardiol. 2005;45(6):828\u201331.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"135_CR91","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jama.287.2.210","volume":"287","author":"J Mehilli","year":"2002","unstructured":"Mehilli J, et al. Sex-based analysis of outcome in patients with acute myocardial infarction treated predominantly with percutaneous coronary intervention. JAMA. 2002;287(2):210\u20135.","journal-title":"JAMA"},{"issue":"14","key":"135_CR92","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1001\/jama.284.14.1799","volume":"284","author":"J Mehilli","year":"2000","unstructured":"Mehilli J, et al. Differences in prognostic factors and outcomes between women and men undergoing coronary artery stenting. JAMA. 2000;284(14):1799\u2013805.","journal-title":"JAMA"},{"issue":"8","key":"135_CR93","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/jama.2009.1227","volume":"302","author":"JS Berger","year":"2009","unstructured":"Berger JS, et al. Sex differences in mortality following acute coronary syndromes. JAMA. 2009;302(8):874\u201382.","journal-title":"JAMA"},{"issue":"11","key":"135_CR94","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/eurheartj\/ehl005","volume":"27","author":"C Daly","year":"2006","unstructured":"Daly C, et al. The impact of guideline compliant medical therapy on clinical outcome in patients with stable angina: findings from the Euro Heart Survey of stable angina. Eur Heart J. 2006;27(11):1298\u2013304.","journal-title":"Eur Heart J"},{"issue":"3","key":"135_CR95","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ccd.24800","volume":"82","author":"I Wijnbergen","year":"2013","unstructured":"Wijnbergen I, et al. Gender differences in long-term outcome after primary percutaneous intervention for ST-segment elevation myocardial infarction. Catheter Cardiovasc Interv. 2013;82(3):379\u201384.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"7","key":"135_CR96","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1161\/CIRCULATIONAHA.106.685859","volume":"115","author":"RD Anderson","year":"2007","unstructured":"Anderson RD, Pepine CJ. Gender differences in the treatment for acute myocardial infarction: bias or biology? Circulation. 2007;115(7):823\u20136.","journal-title":"Circulation"},{"issue":"24","key":"135_CR97","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/eurheartj\/ehr349","volume":"32","author":"J Alfredsson","year":"2011","unstructured":"Alfredsson J, et al. Similar outcome with an invasive strategy in men and women with non-ST-elevation acute coronary syndromes: from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Eur Heart J. 2011;32(24):3128\u201336.","journal-title":"Eur Heart J"},{"issue":"1","key":"135_CR98","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/hrt.2007.138537","volume":"95","author":"S Dey","year":"2009","unstructured":"Dey S, et al. Sex-related differences in the presentation, treatment and outcomes among patients with acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart. 2009;95(1):20\u20136.","journal-title":"Heart"},{"key":"135_CR99","doi-asserted-by":"crossref","unstructured":"Diercks DB, et al. Gender differences in time to presentation for myocardial infarction before and after a national women\u2019s cardiovascular awareness campaign: a temporal analysis from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation (CRUSADE) and the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get with the Guidelines (NCDR ACTION Registry-GWTG). Am Heart J. 2010;160(1):80\u201387 e3.","DOI":"10.1016\/j.ahj.2010.04.017"},{"issue":"24","key":"135_CR100","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1001\/jama.288.24.3124","volume":"288","author":"R Glaser","year":"2002","unstructured":"Glaser R, et al. Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA. 2002;288(24):3124\u20139.","journal-title":"JAMA"},{"issue":"16","key":"135_CR101","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0195-668X(03)00320-8","volume":"24","author":"J Mehilli","year":"2003","unstructured":"Mehilli J, et al. Gender and restenosis after coronary artery stenting. Eur Heart J. 2003;24(16):1523\u201330.","journal-title":"Eur Heart J"},{"issue":"6","key":"135_CR102","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.amjcard.2010.10.068","volume":"107","author":"VG Ng","year":"2011","unstructured":"Ng VG, et al. Three-year results of safety and efficacy of the everolimus-eluting coronary stent in women (from the SPIRIT III randomized clinical trial). Am J Cardiol. 2011;107(6):841\u20138.","journal-title":"Am J Cardiol"},{"issue":"20","key":"135_CR103","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/j.jacc.2013.02.030","volume":"61","author":"SL Daugherty","year":"2013","unstructured":"Daugherty SL, et al. Patterns of use and comparative effectiveness of bleeding avoidance strategies in men and women following percutaneous coronary interventions: an observational study from the National Cardiovascular Data Registry. J Am Coll Cardiol. 2013;61(20):2070\u20138.","journal-title":"J Am Coll Cardiol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0135-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0135-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0135-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T15:56:07Z","timestamp":1596729367000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0135-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,24]]},"references-count":103,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["135"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0135-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,24]]}}}